We came across a bullish thesis on Genmab A/S (GMAB) on Substack by Oliver | MMMT Wealth. In this article, we will summarize ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $25.00. The ...

The share buy-back program will start on March 26, 2025, and is expected to end no later than July 10, 2025 (unless Genmab terminates or suspends the program).

Investing.com -- Shares of Genmab (NASDAQ: GMAB) fell 3.8% as the biotech company faces a legal challenge from AbbVie Inc ...

Shares of NASDAQ GMAB opened at $19.84 on Friday. The stock has a fifty day moving average price of $21.09 and a 200 day moving average price of $22.25. Genmab A/S has a 1-year low of $18.64 and a ...

Equities researchers at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Genmab A/S in a research note issued on Tuesday, March 18th. William Blair analyst M. Phipps ...

Danish biotech (Nasdaq: GMAB) on Saturday revealed that US pharma major (AbbVie (NYSE: ABBV) has filed a complaint in the US ...

OmniAb’s (OABI) stock tumbled roughly 25% this week after financial results for Q4 reflected a mix of revenue growth tempered by a downturn in ...

Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle)Genmab categorically refutes allegations and will vigorously ...

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. Genmab A/S has moved -37.4% over the last year ...